Total
0
Shares
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker
CEO and MD, Michael Baker
Source: Suda Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • SUDA Pharmaceuticals (SUD) enters an exclusive licence and distribution agreement with STADA Pharmaceuticals for its sleep spray in Australia
  • ZolpiMist is a fast-acting oral spray for the treatment of insomnia
  • Under the agreement, SUDA will receive an upfront fee of $170,000, a milestone payment of $40,000 and gain a 10 per cent royalty based on net sales of ZolpiMist
  • SUDA Pharmaceuticals closed up 2.13 per cent to 4.8 cents on August 24

SUDA Pharmaceuticals (SUD) has entered an exclusive licence and distribution agreement for ZolpiMist in Australia.

The agreement was signed with STADA Pharmaceuticals Australia, a member of the global, German-based STADA Group.

Under the agreement, SUDA will receive an upfront fee of $170,000 plus a milestone payment of $40,000.

SUDA will also gain a 10 per cent royalty, based on net sales of ZolpiMist, which it will manufacture and supply at an agreed price.

ZolpiMist is a fast-acting oral spray for the treatment of insomnia. The product is said to reduce sleep latency and be easy to consume without water or swallowing, unlike conventional tablets.

According to a survey conducted by the University of Southampton, the number of people suffering from sleep problems rose from one in six, to one in four during the COVID-19 pandemic.

Clinical data has demonstrated a faster onset of action using ZolpiMist over conventional tablet forms of the drug, a critical factor for an effective anti-insomnia medication.

SUDA’s Executive Director of Business Development David Phillips said the company was excited about developing its partnership with STADA, which it said had strong credentials to successfully market ZolpiMist in Australia.

“By completing an agreement in Australia, we continue to make progress for the commercial build out of ZolpiMist,” Mr Phillips said.  

“This partnership is anticipated to lead to SUDA’s first revenue stream from the commercialisation of a product from our portfolio.”

SUDA Pharmaceuticals closed up 2.13 per cent to 4.8 cents on August 24.  
      

SUD by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.